Table 4

CVD mortality rates per 100 000 person-years in four population-based cohort studies in Iran, ages 40–65 years

10-year CVD mortality, nPerson-yearsCrude mortality rate (95% CI)Direct standardised mortality rate (95% CI)*Direct standardised mortality rate
(95% CI)†
Multivariable adjusted HRs‡P values
Total
 TLGS6642 787158 (125 to 202)153 (115 to 191)183 (139 to 228)1
 ICS5632 223178 (137 to 231)173 (127 to 218)196 (144 to 249)1.17 (0.82–1.67)0.394
 GCS10803 61 418303 (285 to 321)324 (304 to 344)366 (343 to 389)2.30 (1.79–2.96)<0.001
 ShECS2722 744119 (82 to 174)118 (72 to 163)133 (81 to 184)0.85 (0.54–1.34)0.477
Women
 TLGS2424 314101 (68 to 150)95 (57 to 134)118 (71 to 165)1
 ICS2016 641123 (79 to 191)121 (68 to 175)131 (72 to 190)1.27 (0.70–2.29)0.434
 GCS5402 13 755256 (235 to 278)274 (251 to 298)316 (288 to 344)3.03 (2.01–4.59)<0.001
 ShECS1113 56681 (45 to 147)76 (31 to 121)87 (34 to 139)1.02 (0.49–2.09)0.963
Men
 TLGS4218 473235 (174 to 318)211 (146 to 276)251 (175 to 328)1
 ICS3615 582236 (170 to 327)222 (148 to 296)262 (175 to 349)1.09 (0.70–1.71)0.693
 GCS5401 47 663371 (341 to 404)374 (342 to 406)426 (388 to 463)1.92 (1.38–2.63)<0.001
 ShECS169178175 (107 to 285)145 (74 to 215)173 (87 to 259)0.76 (0.42–1.36)0.353
  • *Age adjustment based on Iranian national census.

  • †Age adjustment based on ‘European’ standard population.

  • ‡HRs based on Cox model adjusted by age, sex, hypertension, smoking, self-reported diabetes and body mass index.

  • CVD, cardiovascular disease; GCS, Golestan Cohort Study (phase 1); ICS, Isfahan Cohort Study; ShECS, Shahroud Eye Cohort Study; TLGS, Tehran Lipid and Glucose Study.